Intelligence Feed event · Equity · 2026-10-04

    Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian Cancer

    Question

    Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian Cancer

    Direct answer

    Genmab released top-line clinical data from the Phase 2 RAINFOL-01 study evaluating antibody-drug conjugate candidate rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The trial achieved an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and median progression-free survival of 9.5 months, supporting advancement into late-stage development.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian Cancer”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-phase-2-trial-for-rina-s-demonstrates-45-9-orr-in-ovarian-cancer-a14f51

    EQUITY
    Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian Cancer
    Genmab released top-line clinical data from the Phase 2 RAINFOL-01 study evaluating antibody-drug conjugate candidate rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The trial achieved an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and median progression-free survival of 9.5 months, supporting advancement into late-stage development.
    GMAB
    Impact
    69
    OCT 4
    SIG
    90%
    GMAB
    Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian Cancer
    Genmab released top-line clinical data from the Phase 2 RAINFOL-01 study evaluating antibody-drug conjugate candidate rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The trial achieved an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and median progression-free survival of 9.5 months, supporting advancement into late-stage development.
    → Positive Phase 2 oncology data (45.9% ORR, 9.5m PFS) increases commercialization probability and pipeline asset valuation for GMAB.
    Impact
    Genmab released top-line clinical data from the Phase 2 RAINFOL-01 study evaluating antibody-drug conjugate candidate rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The trial achieved an objective response rate of 45.9%, accompanied by a median duration of response of 12.1 months and median progression-free survival of 9.5 months, supporting advancement into late-stage development.
    Affected
    GMAB
    Transmission
    Positive Phase 2 oncology data (45.9% ORR, 9.5m PFS) increases commercialization probability and pipeline asset valuation for GMAB.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABbiotech pipeline derisking and oncology franchise market value adjustmentUp1-5dGenmab announced Phase 2 results for Rina-S in platinum-resistant ovarian cancer, demonstrating a 45.9% objective response rate with a median duration of response of 12.1 months.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month